SCHEMBL365074

SCHEMBL365074

CCCC1CCC(=O)c2cn(Cc3ccc(OC)cc3)nc21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.43
CMA1 P23946 1/20 0.38
GAA P10253 1/20 0.37
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
CYP26A1 O43174 1/20 0.36
CYP24A1 Q07973 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
CRBN Q96SW2 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365625 0.85 SIGMAR1 (0.41) AADATCMA1GAAKDM4EHKDC1
SCHEMBL15182504 0.84 AADAT (0.46) AADATCMA1GAAGSK3AGSK3B
SCHEMBL366654 0.83 AADAT (0.44) AADATCMA1GAAGSK3AGSK3B
SCHEMBL6837296 0.80 AADAT (0.43) AADATCMA1GAAGSK3AGSK3B
SCHEMBL6837350 0.76 AADAT (0.43) AADATCMA1GAAGSK3AGSK3B
SCHEMBL7670133 0.76 AADAT (0.47) AADATCMA1GAAGSK3AGSK3B
SCHEMBL365744 0.76 AADAT (0.47) AADATCMA1GAAGSK3AGSK3B
SCHEMBL366071 0.76 AADAT (0.50) AADATCMA1GAAGSK3AGSK3B
SCHEMBL6837301 0.75 ALDH1A1 (0.48) AADATCMA1GAAGSK3AGSK3B
SCHEMBL365659 0.75 ALDH1A1 (0.48) AADATCMA1GAAGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885CMA1 4844/4885GAA 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.